[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of California, Irvine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":660},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,85,0,25,[9,48,72,100,135,165,198,224,250,272,297,317,343,381,407,436,460,488,507,530,551,570,595,613,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652667","vr-cognitive-behavioral-therapy-prehabilitation-for-spinal-deformity-surgery-100652667",false,"NCT07777679","VR-Cognitive Behavioral Therapy Prehabilitation for Spinal Deformity Surgery","A Randomized Controlled Pilot Trial Evaluating Virtual Reality-Based Cognitive Behavioral Therapy (VR-CBT) as a Prehabilitation Intervention for Adult Spinal Deformity Surgery","VR-CBT","Inclusion Criteria:\n\n* Adults between 18 and 75 years old.\n\nDiagnosis of thoracolumbar adult spinal deformity (ASD), including but not limited to adult scoliosis, kyphosis, or spondylolisthesis, confirmed radiographically using SRS-Schwab classification criteria.\n\nScheduled for elective spinal surgery involving fusion of more than four spinal levels.\n\nModerate to severe chronic pain, assessed using the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS).\n\nAbility to participate in an 8-week preoperative prehabilitation program.\n\nAdequate cognitive functioning and English language skills to engage in CBT or VR-CBT treatments.\n\nAbility to provide written informed consent and adhere to study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Neurological conditions that significantly impact cognition or mobility.\n\nActive spinal infection, malignancy, or significant spinal trauma.\n\nUnmanaged medical conditions that could affect participation in the study.\n\nPregnancy or plans to become pregnant during the study period.\n\nSevere visual impairment, claustrophobia, or other conditions that prevent safe use of VR technology.\n\nCognitive impairment preventing adherence to study procedures.\n\nHistory of non-compliance with medical treatment or failure to adhere to study visits and follow-up.","ALL","18 Years","75 Years",{"count":22,"type":23},80,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn whether a virtual reality-based cognitive behavioral therapy (VR-CBT) prehabilitation program can improve recovery and quality of life for adults undergoing elective spine surgery. The main questions it aims to answer are:\n\nDoes participating in an 8-week VR-CBT prehabilitation program before surgery improve physical function and pain-related outcomes at 12 months after surgery?\n\nDoes VR-CBT prehabilitation reduce postoperative anxiety, depression, and pain interference compared with usual preoperative care?\n\nResearchers will compare participants who receive the VR-CBT prehabilitation program plus usual care to participants who receive usual preoperative care alone to see if the VR-CBT program leads to better recovery and patient-reported outcomes.\n\nParticipants will:\n\nUse a VR headset at home to complete structured CBT-based prehabilitation sessions over 8 weeks before surgery.\n\nAttend routine clinic visits and complete questionnaires about pain, function, mood, and quality of life before surgery and through 12 months after surgery.\n\nAllow the research team to review their medical records for information about surgery, complications, and postoperative recovery.",[29,30],"Degenerative Spine Disease","Spinal Stenosis Lumbar",[32,33,34],"Virtual reality-based cognitive behavioral therapy","Patient-reported outcomes","Spine surgery prehabilitation","NOT_YET_RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":23},"2026-09-01",{"date":43,"type":23},"2028-11-28",{"name":45,"class":46},"University of California, Irvine","OTHER",2,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100504175","patient-derived-vascularized-microtumor-model-of-gastrointestinal-peritoneal-carcinomatosis-100504175","NCT05844865","Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis","Inclusion Criteria:\n\n* Patients must have a GI tumor\n* Must have planned standard of care surgical procedure\n* Age ≥ 18 years.\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n\\- Pattens who are unable to comply with the study protocol",{"count":55,"type":23},20,[26],"This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites\u002Fperitoneal wash fluid, tumor samples during their planned surgical procedure.",[59,60],"Peritoneal Carcinomatosis","Gastrointestinal Peritoneal Carcinomatosis",[59,60],"RECRUITING","2026-08-12",{"date":65,"type":39},"2026-08-14",{"date":67,"type":39},"2023-05-04",{"date":69,"type":23},"2026-12",{"name":45,"class":46},1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":18,"minAge":19,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":71},"100437106","using-nicotine-to-reverse-age-related-auditory-processing-deficits-100437106","NCT04971954","Using Nicotine to Reverse Age-related Auditory Processing Deficits","Using Nicotine to Reverse Age-related Auditory Processing Deficits: Human Psychophysics and Electrophysiology","Nicotine","Inclusion Criteria:\n\n* between 18 and 85 years of age\n* non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking dependency\n* cognitive performance within two standard deviations of the CERAD mean\n\nExclusion Criteria:\n\n* less than 18 or greater than 85 years of age\n* deafness or excessive hearing loss\n* smokers with a score between 3 and 10 on the Fagerström index of smoking dependency\n* history of psychiatric illness, neurological disorders, diabetes mellitus, renal failure, or cardiovascular disease\n* regular use of prescription medications (excluding oral contraceptives)\n* drug dependency",true,"85 Years",{"count":83,"type":23},48,[26],"The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.",[87,88],"Auditory Perceptual Impairment","Aging",[90,91],"nicotine","biomarker","2026-08-06",{"date":94,"type":39},"2026-08-10",{"date":96,"type":39},"2022-02-01",{"date":98,"type":23},"2026-12-31",{"name":45,"class":46},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":71},"100638426","early-phase-1-feasibility-study-on-the-effect-of-a-methionine-reduced-diet-on-serum-levels-in-pts-w-solid-tumors-100638426","NCT07628634","Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w\u002F Solid Tumors","Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients With Solid Tumors","Inclusion Criteria:\n\n* Age: Subjects must be 18 years of age or older.\n* Diagnosis: Has a diagnosis of metastatic, recurrent, or unresectable solid tumors.\n* Life Expectancy: Subjects must have an expected life expectancy of at least 3 months.\n* Performance Status: Subjects must have an ECOG performance status of 0-2.\n* Organ Function: Subjects must have adequate organ function, as determined by the investigator through review of standard labs.\n* Pregnancy and Contraception: Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to study enrollment and must agree to use adequate contraception throughout the study period and for 30 days after the last dose of study treatment. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n* Dietary Compliance: Subjects must be willing and able to comply with the methionine-reduced diet as prescribed by the study protocol.\n* Informed Consent: Subjects or Legally Authorized Representatives (LAR) must provide written informed consent prior to any study-specific procedures, indicating that they understand the purpose of the study and are willing to comply with its requirements.\n* Able to receive systemic standard of care cancer therapy.\n\nAdditional criteria specifically for the glioma population:\n\n* Diagnosis: Histopathological proven diagnosis: a) newly diagnosed grade 2-3 glioma or b) all grades for recurrent glioma.\n* Treatment: Subjects must be able to receive radiation therapy and\u002For chemotherapy as a part of their treatment.\n\nExclusion Criteria:\n\n* Brain Metastases: Subjects with uncontrolled or symptomatic brain metastases. Subjects with brain metastases that have been treated, are asymptomatic, and patients who require steroids are eligible.\n* Significant Clinical Illness: Subjects with uncontrolled significant clinical illnesses, including but not limited to: a) Active infections requiring systemic therapy. b) Severe cardiovascular conditions such as recent myocardial infarction (within 6 months), uncontrolled angina, congestive heart failure (NYHA class III or IV), or significant arrhythmias. (c) Uncontrolled diabetes.\n* Significant Amino Acid\u002FMetabolic Illnesses: Subjects with severe or inherited illnesses that affect metabolism of amino acids or disrupt nutrient absorption, including but not limited to: a) Severe liver disease, such as cirrhosis or severe hepatic insufficiency, that may have compromised ability to metabolize amino acids. b) Inherited metabolic disorders, such as homocystinuria or other disorders affecting sulfur amino acid metabolism, that may have potential metabolic imbalances. c) Severe gastrointestinal disorders, such as active inflammatory bowel disease (IBD), short bowel syndrome, or other conditions that significantly impair nutrient absorption, that may lead to nutritional deficiencies and gastrointestinal complications.\n* Recent Surgery: Major surgery within 4 weeks of randomization (biopsies are acceptable per investigator judgement)\n* Concurrent Malignancies: Subjects with another malignancy that requires active treatment during the study period or is expected to interfere with the study intervention.\n* Pregnancy or Lactation: Female subjects who are pregnant or breastfeeding.\n* Malnutrition: Subjects with severe malnutrition or significant nutritional deficiencies per investigator's discretion.\n* Substance Abuse: Subjects with a history of substance abuse or dependency within the past 6 months that, in the opinion of the investigator, would interfere with adherence to study requirements.\n* Subjects with chronic kidney disease with advanced stages 3b or higher.\n* Psychiatric Disorders: Subjects with psychiatric disorders that would interfere with the ability to give informed consent or adhere to study requirements per investigator judgment.\n* Subjects with known allergies or intolerances to low-methionine foods.\n* Subjects with any medical or surgical conditions that, in the opinion of the investigator, would make adherence to the methionine-reduced diet unsafe or impractical.",{"count":7,"type":23},[109],"EARLY_PHASE1","This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.",[112,113,114,115,116,117,118,119,120,121,122,123,124,125,126],"Adenocarcinoma","Basal Cell Carcinoma","Squamous Cell Carcinoma","Transitional Cell Carcinoma","Ductal Carcinoma","Osteosarcoma","Soft Tissue Sarcoma","Ewing Sarcoma","Rhabdomyosarcoma","Leiomyosarcoma","Melanoma","Germ Cell Tumor","Lymphoma","Endocrine Tumor","Glioma","2026-07-29",{"date":129,"type":39},"2026-07-31",{"date":131,"type":39},"2026-05-01",{"date":133,"type":23},"2028-05-01",{"name":45,"class":46},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":143,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":154,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100609081","secondary-cervical-cancer-prevention-of-vulnerable-women-with-hpv-and-hiv-co-infection-in-india-100609081","NCT07209917","Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India","Secondary Cervical Cancer Prevention of Vulnerable Women With Human Papillomavirus (HPV) and Human Immunodeficiency Virus (HIV) Co-infection in India","SAKHI","Inclusion Criteria:\n\n1. WLH, 25 - 50 years of age; based on HIV-based guidelines;\n2. Receiving ART for \\> 12 months to ensure medication stabilization, and ensure any impact on the cervical cancer outcomes will not be attributed solely to recent ART initiation, as validated by an ART card given to all ART patients;\n3. Screened as HPV positive by RT-PCR (Reverse Transcription Polymerase Chain Reaction) for oncogenic genes; and assessed to be VIA negative;\n4. Have not participated in Phase I Formative Study.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women due to hormonal and dietary guideline differences;\n2. Women older than age 50 These women will be immediately referred to a gynecology specialist.","FEMALE","25 Years","50 Years",{"count":147,"type":23},348,[26],"Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavirus (HPV) may result in persistent HR-HPV infection, a critical risk factor for progression of HPV-related cervical oncogenesis. Progression of precancerous lesions among women living with HIV (WLH) is also associated with: 1) lack of HPV screening; 2) high levels of depressive symptoms and stigma; and 3) malnutrition, which negatively impacts the activation and proliferation of immune cells. Yet programs that offer WLH with comprehensive services focused on HPV screening and psychological and nutritional support are almost non-existent, and the gap is critical. Nutrition plays an integral role in relationship to HPV\u002FHIV co-infection, as demonstrated by an increased risk of HR-HPV associated with poor nutrition; nutritional deficiencies are likewise linked to cervical intra-epithelial neoplasia. The immunological effect of malnutrition may also be exacerbated among WLH due to elevated energy demands of chronic immune activation; worsened with HPV\u002FHIV co-infection. Further, depressive symptoms (aka depression for brevity) partially mediate the effect of food insecurity on HIV viral suppression. In our completed ASHA-Nutrition R01 study of antiretroviral (ART) adherence, the investigators trained lay community health peer counselors, named Accredited Social Health Activist (ASHA), to improve the health of 600 rural WLH by providing emotional support, skill-building, nutrition education, and\u002For protein-enriched food supplements. In that study, our intervention, co-delivered by our trained peer counselors, and guided by nurses, led to increased CD4+ T cell recovery and improved anthropometric and psychosocial outcomes. The investigators found that peer counselors support plus protein supplements and nutritional education were significantly associated with improved CD4 counts and increased lean mass at 18 months (P \\\u003C 0.001), as well as significant improvements in depression, ART adherence, social support and internalized stigma. In our sub study, CC screening of 598 of these WLH revealed that 13% were found to have abnormal cervical lesions and 4 (1%) had squamous CC. Preliminary evidence also revealed that nutritional supplements may be associated with a 40% reduction in the risk of abnormal cervical lesions (adjusted odds ratio \\[aOR\\] = 0.60), with an association between serum albumin and reduced risk of abnormal lesions (aOR= 0.39).\n\nWith a focus on secondary prevention of CC, the investigators hope to mitigate the link between HR-HPV persistence and risk of CC as well as improve the health of women co-infected with HPV\u002FHIV (W-Co-V). Our stellar team plans to build upon our prior ASHA-Nutrition intervention, using formative research to refine a nurse-led, peer counselors co-delivered, nutrition-enhanced SAKHI HPV intervention, adapted for W-Co-V. This will be followed by a randomized controlled trial (RCT), assessing the efficacy of our refined comprehensive, multifaceted SAKHI HPV intervention, as compared with an enhanced Standard of Care (SOC+) (usual care + 3 sessions \\[wellness, basic nutrition and HPV\u002FHIV health promotion\\]) among 348 high-risk co-infected women to prevent CC while remaining engaged in the HIV treatment cascade, and managing nutritional health. Recruited participants will be individually randomized in a 1:1 ratio to one of the two study arms. Our Primary outcome is HR-HPV persistence (2 positive tests for the same HR-HPV type, separated by 12-18 months). The two aims incorporating RCT interventions are as follows:\n\nAim 2. To evaluate the efficacy of SAKHI HPV intervention among 348 W-Co-V on the primary outcome (HR-HPV persistence) as compared to the Enhanced Standard of Care (SOC+) program. H2: Compared to the SOC+ participants, SAKHI participants will have lower rates of HR-HPV persistence.\n\nAim 3. Assess the impact of the SAKHI program secondarily on: 1) HIV indices (HIV viral load; CD4 count); 2) Nutritional index (serum albumin) at 6-, 12-, and 18-months.",[151,152,153],"Cervical Cancer","Human Papillomavirus (HPV) Infection","Human Immunodeficiency Virus (HIV) Infection",[155,156,157],"Cervical Cancer Prevention","HPV-HIV Co-Infection","ASHA-Nutrition",{"date":129,"type":39},{"date":160,"type":39},"2026-02-01",{"date":162,"type":23},"2029-04-30",{"name":45,"class":46},4,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100647699","empowering-patients-lung-cancer-screening-uptake-empower-lcscall-100647699","NCT07711691","Empowering Patients' Lung Cancer Screening Uptake (Empower LCS\u002FCall+)","Empowering Patients' Lung Cancer Screening Uptake (Empower LCS\u002FCall+): A Multi-Site Pilot Randomized Controlled Trial","Empower LCS+","Inclusion Criteria:\n\n1. Must meet current USPSTF eligibility criteria for lung cancer screening (Current criteria: age 50-80 years old with a 20 pack-year smoking history, who currently smoke or have quit within the last 15 years)\n2. Must have an electronic health record-assigned primary care provider within University of California Irvine Health or Emory Healthcare\n3. Must have recent engagement with respective health system (i.e., office or emergency department (ED) visit, hospitalization with discharged home in the last 12 months, or a scheduled office visit in the next 3 months).\n4. Must speak English or Spanish\n5. Able and willing to provide informed consent\n\nExclusion Criteria:\n\n1. Meet the eligibility upper age limit during initial 4-month participation.\n2. Have a prior history of lung cancer.\n3. Have a new diagnosis of other cancers in the 12 months\n4. Have a chest CT or LDCT in the last 12 months\n5. Have ICD-10 code of Alzheimer's disease in EHR","80 Years",{"count":22,"type":23},[26],"Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screening do not receive it. The purpose of the Empower LCS\u002FCall+ study is to evaluate new strategies to improve lung cancer screening among adults who are eligible for screening based on current U.S. Preventive Services Task Force (USPSTF) guidelines.\n\nThis pilot randomized controlled trial will enroll approximately 80 participants from UC Irvine Health and Emory Healthcare. Participants will be randomly assigned to receive either enhanced usual care or the Empower LCS\u002FCall+ intervention. The intervention includes educational materials, reminders for patients and primary care providers, and information about financial and community resources when appropriate. Participants who do not complete lung cancer screening after the initial intervention may receive additional telephone-based navigation through the Call+ program to help identify and address barriers to screening and help with scheduling.\n\nParticipants will complete a baseline survey and follow-up surveys at 4 and 8 months, and researchers will review electronic health record information to determine whether lung cancer screening was discussed, ordered, and completed. Some participants will also be invited to complete a one-time interview about their experiences with the study.\n\nThe results of this study will help determine the feasibility, acceptability, and preliminary effectiveness of the Empower LCS\u002FCall+ intervention and will inform future efforts to improve equitable access to lung cancer screening.",[178,179,180,181],"Lung Cancer Screening","Lung Neoplasms","Smoking ( Cigarette)","Early Detection of Cancer",[183,184,185,186,187,188,189],"Lung cancer screening","Low-dose computed tomography (LDCT)","Patient navigation","Natural language processing","Smoking","Health-related social needs","Multilevel intervention","2026-07-20",{"date":192,"type":39},"2026-07-22",{"date":41,"type":23},{"date":195,"type":23},"2028-12",{"name":45,"class":46},57,{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":24,"phases":208,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":71},"100542588","phase-2-an-acupuncture-study-for-people-at-high-risk-for-sepsis-100542588","NCT06344819","An Acupuncture Study for People At High Risk for Sepsis","Acupuncture to Improve Outcomes in Sepsis Patient: The ACTIONS Trial","ACTIONS","Inclusion Criteria:\n\n* Age 18 or older\n* Having a sepsis order-set placed within the previous 48 hours\n\nExclusion Criteria:\n\n* The study Principal Investigator will review the medical record again prior to enrollment to exclude non-sepsis patients (Even though the placement of sepsis order set already screens out such patients, subsequent clinical development after sepsis order set placement may generate new information that deems the patient not septic.)\n* Admitted to ICU before being approached for consenting\n* Having an implanted medical device, such as a pacemaker or implantable cardioverter-defibrillator (ICD), with which electroacupuncture\n* Unable to obtain informed consent due to a participant's mental status and absence of an individual authorized to give consent on the participant's behalf\n* The patient is on an interventional clinical trial and its Principal Investigator does not give approval to enrollment to this study (e.g. genomic profiling, biospecimen, or observational studies do not require PI approval).",{"count":207,"type":23},78,[209],"PHASE2","Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham acupuncture is performed the same way as real acupuncture but will use different needles and target different sites or places on the body than real acupuncture.",[212],"Sepsis",[214,215],"sepsis","acupuncture","2026-07-19",{"date":218,"type":39},"2026-07-21",{"date":220,"type":39},"2024-03-20",{"date":222,"type":23},"2028-03-20",{"name":45,"class":46},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":71},"100550928","phase-2-cmv-tcip-directed-letermovir-prophylaxis-after-allo-sct-100550928","NCT06453460","CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT","Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* ≥ 18 years of age on the day of signing informed consent.\n* Karnofsky performance \\>70%\n* Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.\n* Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.\n* Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.\n* Must be within Day-10 thru Day+28 days of planned HSCT at the time of enrollment.\n* Be able to comply with medical recommendations or follow-up.\n* Has adequate organ functions determined by\n\n  1. Serum creatinine clearance ≥50 ml\u002Fmin (calculated with Cockroft-Gault formula).\n  2. Bilirubin ≤1.5 mg\u002Fdl except for Gilbert's disease.\n  3. ALT or AST ≤200 IU\u002Fml for adults.\n  4. Conjugated (direct) bilirubin \\\u003C 2x upper limit of normal.\n  5. Left ventricular ejection fraction ≥40%.\n  6. Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.\n\nExclusion Criteria:\n\n* Has a history of CMV end-organ disease or CS-CMVi within 6 months prior to enrollment.\n* Received within 7 days prior to screening or plans to receive during the study any of the following:\n\n  1. Ganciclovir\n  2. Valganciclovir\n  3. Foscarnet\n  4. Acyclovir (\\> 3200 mg PO per day or \\> 25 mg\u002Fkg IV per day)\n  5. Valacyclovir (\\> 3000 mg\u002Fday)\n  6. Famciclovir (\\> 1500 mg\u002Fday)\n* Received within 30 days prior to screening or plans to receive during the study any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent\u002Fbiologic therapy.\n* Has suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations.\n* Has an uncontrolled infection\n* Requires mechanical ventilation or is hemodynamically unstable",{"count":232,"type":23},50,[209],"This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.",[236,237],"CMV","Allogeneic Stem Cell Transplantation",[239,240,241,242],"CMV T Cell Immunity Panel","CMV reactivation","Allogeneic stem cell transplantation","Letermovir","2026-07-17",{"date":218,"type":39},{"date":246,"type":39},"2024-06-27",{"date":248,"type":23},"2029-06",{"name":45,"class":46},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":24,"phases":259,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":164},"100484341","phase-4-decolonization-to-reduce-after-surgery-events-of-surgical-site-infection-100484341","NCT05586776","Decolonization to Reduce After-Surgery Events of Surgical Site Infection","DECREASE SSI","Inclusion Criteria:\n\n* 18 years of age or older\n* Recent open (not solely laparoscopic) surgery involving an abdominal incision within the past 14 days. For cesarean section, recruitment restricted to BMI ≥ 40.\n* Able to communicate regularly by phone\n* Able to bathe, shower or have this task performed by a caregiver\n\nExclusion Criteria:\n\n* Transfer to an acute care hospital\n* Discharged to receive end-of-life hospice measures\n* Discharged more than 14 days after surgery\n* Allergic to mupirocin and\u002For chlorhexidine\n* Active infection at enrollment\\*\n\n  \\*Refers to\n  1. Infections requiring systemic antibacterial agents, so viral illness (e.g., COVID, flu) is not an exclusion.\n  2. Topical antibacterial agents do not count toward exclusion (e.g., topical products for acne)\n  3. Prophylactic antibacterial agents do not count toward exclusion\n* Surgical incision not closed at discharge",{"count":258,"type":23},2700,[260],"PHASE4","The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.",[263],"Surgical Site Infection",[263,265],"SSI",{"date":218,"type":39},{"date":268,"type":39},"2023-01-17",{"date":270,"type":23},"2027-12",{"name":45,"class":46},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":71},"100597863","phase-1-trial-of-single-protein-encapsulated-doxorubicin-spedox-6-in-advanced-malignancies-100597863","NCT07064018","Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","Phase Ib\u002FIIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","Inclusion Criteria:\n\n* Subjects ≥ 18 years at the first screening examination\u002Fvisit.\n* Subjects with advanced histologically or cytologically confirmed solid tumors (see below) refractory to or relapse from at least two previous therapies.\n* Tumor types expected to express lower levels of FcRn relative to normal tissue including: STS, TNBC, cervical cancer, NSCLC, ovarian cancer, and KRAS mutated pancreatic ductal adenocarcinoma without requirement for testing FcRn level.\n* Disease that is considered measurable by RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy of at least 12 weeks.\n* Human Immunodeficiency Virus (HIV)-positive trial participants should be on established antiretroviral therapy (ART) for at least four weeks and have an HIV viral load less than 400 copies\u002FmL prior to enrollment.\n* Left ventricular ejection fraction \\> 50%.\n* Adequate organ function: (Hb ≥10 g\u002FdL, ANC ≥1,000\u002FµL3, and platelets\n\n  ≥100,000\u002FµL3), serum bilirubin ≤.5x the institutional upper limit of normal (ULN) (unless known Gilbert's disease), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤3x ULN, and creatinine clearance \\>50 mL\u002Fmin as assessed by Cockcroft-Gault equation.\n* For patients with known Gilbert's disease, serum unconjugated bilirubin must be \\\u003C 4 mg\u002FdL.\n* Patient must have washed out of prior chemotherapy (at least 3 weeks from last end of therapy), radiotherapy (at least 4 weeks from last end of therapy), immunotherapy (at least 4 weeks from last end of therapy), other targeted therapies (at least 4 weeks from last end of therapy), or surgery (at least 4 weeks).\n* Recovery from toxicities of prior therapy. Toxicities should have recovered to CTCAE grade ≤ 1 or baseline with exception of alopecia.\n* Females of reproductive potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment. Additionally, female subjects of reproductive potential should agree to use effective acceptable forms of contraception: surgical sterilization (tubal ligation); total abstinence from sexual intercourse with the opposite sex; established hormonal birth control (e.g., oral, transdermal, injection, or implant) plus a barrier method or a double barrier method (intrauterine device, spermicide, or a diaphragm plus condom) for at least 1 month prior to Cycle 1 Day 1 and agreement to use such a method during study participation and for an additional 6 months after the last dose of SPEDOX-6.\n* For males of reproductive potential: vasectomy or highly effective contraception (e.g., condoms, abstinence) during the study and for an additional 6 months after the last dose of SPEDOX-6.\n\nExclusion Criteria:\n\n* Patients with cancers with known driver mutations for which there are known and effective targeted therapies that have not received those therapies, but are able to. If a patient has received appropriate targeted treatment for their mutations and progressed, or those treatments are contraindicated, they will be considered potentially eligible.\n* Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months before study entry.\n* Untreated metastases to the Central Nervous System (CNS).\n* Have received any prior doxorubicin or anthracycline equivalent.\n* Previous radiation to the mediastinal or pericardial area.\n* A known allergy to albumin.\n* HIV infection with CD4+ count \\\u003C 350 cells\u002FµL or Acquired Immunodeficiency (AIDS)-defining opportunistic infection in previous 12 months.\n* Pregnant (positive serum or urine pregnancy test) or lactating.\n* Previous treatment with an investigational agent or the non-approved use of a drug or device withing 4 weeks of study entry.\n* Uncontrolled diabetes mellitus.\n* Patients who require concomitant use of strong inhibitors or inducers of CYP3A4, CYP2D6 or P-glycoprotein (P-gp).",{"count":280,"type":23},67,[282,209],"PHASE1","This is a Phase 1b\u002FIIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.",[285,286,287,151,288,289],"Soft-tissue Sarcoma","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Ovarian Cancer","KRAS Mutation-Related Tumors","2026-07-15",{"date":243,"type":39},{"date":293,"type":39},"2025-04-30",{"date":295,"type":23},"2031-12-31",{"name":45,"class":46},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":143,"minAge":19,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":24,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":71},"100402428","phase-1-effect-of-nac-on-preventing-chemo-related-cognitive-impairments-in-ovarian-ca-pts-treated-w-pbt-100402428","NCT04520139","Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W\u002F PBT","Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)","Inclusion Criteria:\n\nPost-menopausal females (as defined by lack of menstruation for 12 months or status post oophorectomy)\n\n* Histologic or pathologic diagnosis of stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer\n* Eastern Cooperative Oncology Group (ECOG) ≤2\n* Life expectancy \\> 1 year\n* Status post cytoreductive surgery for ovarian cancer or with planned cytoreductive surgery if treated with neoadjuvant chemotherapy\n* Prescribed a minimum of six cycles of platinum-based chemotherapy\n* Adequate organ function as defined below:\n\n  1. Hemoglobin \\> 9 g\u002FdL\n  2. Leukocytes \\>1,500\u002Fmcl\n  3. Absolute Neutrophil Count \\> 1,000\u002FmcL\n  4. Platelets \\> 125,00\u002FmcL\n  5. total bilirubin Within normal institutional limits\n  6. Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C 2.5 x institutional upper limit of normal\n  7. Serum creatinine \\\u003C 1.5 mg\u002FdL.\n\nExclusion Criteria:\n\n* Prior history of any cancer (other than non-melanoma skin cancer)\n* Chemotherapy, radiation therapy, or erythropoietin treatment within the last 6 months\n* Prior severe head injury\n* Has a history of dementia or other neurodegenerative disorders\n* Has an uncontrolled, treatment-resistant depression or other severe psychiatric illnesses\n* Presence of known brain metastases\n* Has an active infection requiring treatment\n* Known immunosuppressive disease\n* Has active systemic autoimmune diseases such as lupus\n* Receipt of systemic immunosuppressive therapy\n* Known human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C\n* Pregnant of breastfeeding.",{"count":305,"type":23},102,[282,209],"This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).",[288,309],"Cognitive Impairment",[311],"Chemotherapy-Related Cognitive Impairments",{"date":243,"type":39},{"date":314,"type":39},"2026-05-21",{"date":270,"type":23},{"name":45,"class":46},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":24,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":47},"100576319","mechanistic-and-clinical-outcomes-of-a-surgical-innovation-aimed-at-minimizing-gerd-associated-with-vsg-innovate-vsg-100576319","NCT06783751","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With Vertical Sleeve Gastrectomy (INNOVATE-VSG)","INNOVATE-VSG","Inclusion Criteria:\n\n1. Male and female subjects aged 18-65 years\n2. Body mass index (BMI) 35-55 kg\u002Fm2\n3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management\n4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.\n5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery\n6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery\n7. Must be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Hiatal hernia \\>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)\n2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator\n3. Severe gastroparesis\n4. Previous bariatric or anti-reflux procedure\n5. Barrett's esophagus\n6. Subjects requiring mesh treatment at time of procedure\n7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator\n8. Subjects with pacemakers, implantable defibrillators, neurostimulators\n9. Portal hypertension or cirrhosis\n10. Chronic pancreatitis\n11. Active cancer treatment\n12. Inability to tolerate general anesthesia\n13. Uncontrollable coagulopathy\n14. Significant and uncontrolled inflammatory bowel disease\n15. Severe and\u002For uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.\n16. Suicidal ideation or unstable\u002Funtreated major depressive disorder within the past year\n17. Alcohol or substance use disorder within the past year.\n18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months\n19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions\n20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.","65 Years",{"count":327,"type":23},44,[26],"This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.",[331,332,333,334],"Obesity","Bariatric Surgery","Sleeve Gastrectomy","Gastroesophageal Reflux Disease","2026-07-13",{"date":337,"type":39},"2026-07-14",{"date":339,"type":39},"2025-03-21",{"date":341,"type":23},"2028-07-01",{"name":45,"class":46},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":24,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":380,"locationsCount":71},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":351,"type":23},75,[209],"This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[355,356,357,358,359,360,288,361,362,363,364,365,366,367,368,369,370,371,372,122,373,374],"Breast Cancer","Sarcoma","Gastric Cancer","Lung Cancer","Head and Neck Cancer","Colorectal Cancer","Liver Cancer","Genitourinary Cancer","Gynecologic Cancer","Urinary Bladder Cancer","Leukemia","Lymphoid Leukemia","Myeloma Multiple","Prostate Cancer","Pancreas Cancer","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Brain Cancer","Mycosis Fungoides","Kidney Cancer","2026-07-11",{"date":337,"type":39},{"date":378,"type":39},"2024-12-02",{"date":270,"type":23},{"name":45,"class":46},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":395,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":71},"100645799","phase-2-metformin-in-pseudomyxoma-peritonei-secondary-to-appendiceal-mucinous-neoplasms-100645799","NCT07693452","Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Key Inclusion Criteria (complete details available in protocol):\n\n* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent\u002Frefractory disease s\u002Fp cytoreductive surgery(CRS)\u002Fhyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS\u002FHIPEC\n* Age ≥18 years\n* ECOG performance status ≤2\n\nKey Exclusion Criteria (complete details available in protocol):\n\n* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS\u002FHIPEC\n* Patients currently taking metformin for another medical indication\n* Patients with a prior adverse event to administration of metformin",{"count":389,"type":23},15,[209],"This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).",[393,394],"Appendiceal Mucinous Neoplasm","Pseudomyxoma Peritonei",[393,394,396,397,398,399],"Pseudomyxoma Peritoneal","PMP","AMNs","Metformin","2026-07-09",{"date":335,"type":39},{"date":403,"type":39},"2026-06-18",{"date":405,"type":23},"2029-07",{"name":45,"class":46},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":24,"phases":415,"briefSummary":416,"conditions":417,"keywords":423,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":47},"100640163","biofield-therapy-for-the-support-of-immunotherapy-related-symptoms-among-adult-cancer-patients---a-pilot-study-100640163","NCT07581080","Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study","Inclusion Criteria:\n\n* Participants must be greater than 18 years of age.\n* Currently diagnosed with cancer.\n* Actively receiving immunotherapy treatment with ICI (PD1 or -PD-L1 inhibitor (single-agent immunotherapy or immunotherapy in combination with other agents; also including the use of steroids if applicable)\n* Report clinically significant fatigue over the past 7 days.\n* Able to travel to the study site to receive Reiki treatments once a week.\n* Understanding and willing to complete all study procedures.\n* Capable of giving written informed consent.\n* Proficient ability to speak, read, and write in English or Spanish.\n\nExclusion Criteria:\n\n* Individuals currently receiving or received Reiki treatment in the past 30 days\n* Currently diagnosed with a severe psychiatric illness (i.e. schizophrenia, dementia, major depression with suicidal ideations)\n* Currently pregnant or intending to become pregnant during the study timeframe",{"count":414,"type":23},12,[26],"Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms.\n\nThe purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care.\n\nThe secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement.\n\nLastly, the third aim is to explore participants' experiences with Reiki through guided interviews.\n\nParticipants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups:\n\nImmediate Reiki Group:\n\nIf participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience.\n\nWaitlist Group:\n\nIf they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience.\n\nThe investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.",[418,419,420,421,422],"Cancer","Immunotherapy","Fatigue Related to Cancer Treatment","Pain","Stress",[424,419,418,425,426,427],"Reiki","fatigue","pain","biofield therapy","2026-07-08",{"date":430,"type":39},"2026-07-10",{"date":432,"type":39},"2026-04-20",{"date":434,"type":23},"2027-01",{"name":45,"class":46},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":71},"100579443","early-phase-1-proofprincip-intratu-tcells-singldoseimmuncheckpoininhib-gastro-esophage-adenocarcinoma-warid1a-mu-100579443","NCT06824363","ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w\u002FARID1a Mu","Proof of Principle Study Evaluating Single Dose Dual Immune Checkpoint Inhibitors to Increase Intra-tumoral T Cells in Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinomas With ARID1A Mutations: ESR-22-22082","Inclusion Criteria:\n\n* Non metastatic GEC including locally advanced unresectable\n* Treatment naïve\n* Histologically proven adenocarcinoma of the esophagus or the stomach with ARID1a mutation either by liquid biopsy (ctDNA) or tissue NGS\u002FWES\n* MSI-Stable or pMMR\n* Age ≥ 18 years\n* Body weight \\> 66 pounds\n* ECOG ≤ 2\n* Repeat biopsy feasible\n* No clinically significant autoimmune disease\n\nExclusion Criteria:\n\n* Patients with known metastatic disease\n* Prior systemic treatment for esophagus, GEJ, or the stomach adenocarcinoma\n* Patients with uncontrolled autoimmune disease per investigator discretion\n* Inability or refusal to undergo biopsy procedures to obtain tissue samples",{"count":444,"type":23},34,[109],"This is a proof of principle clinical trial determining efficacy of single dose dualimmune checkpoint inhibitors to increase intra-tumoral T cells in esophageal, gastroesophageal junction, and gastric adenocarcinomas. These are subjects who have not previously been treated for their disease, who are willing to undergo biopsy procedures, who's disease has not spread to other parts of the body, who's tumors have ARID1A mutations.",[448,449,450,451],"Solid Tumor, Adult","Malignant Solid Tumor","Stomach Adenocarcinoma","Esophageal Adenocarcinoma","2026-07-02",{"date":454,"type":39},"2026-07-07",{"date":456,"type":39},"2026-05-25",{"date":458,"type":23},"2028-07",{"name":45,"class":46},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":24,"phases":469,"briefSummary":470,"conditions":471,"keywords":474,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":71},"100398793","phase-2-cabozantinib-combined-with-ipilimumabnivolumab-and-tace-in-patients-with-hepatocellular-carcinoma-100398793","NCT04472767","Cabozantinib Combined With Ipilimumab\u002FNivolumab and TACE in Patients With Hepatocellular Carcinoma","Phase 2 Study of Cabozantinib Combined With Ipilimumab\u002FNivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment","Inclusion Criteria:\n\n* Histologic or radiographic diagnosis of hepatocellular carcinoma\n* At least one lesion amenable to TACE treatment\n* Child-Pugh A-B7 (B7 based on Albumin allowed)\n* Not a candidate for resection or transplantation\n* Age ≥ 18 years.\n* Performance status: ECOG performance status ≤2\n* Must have at least one measurable lesion (either untreated or progressed after previous locoregional treatment)\n* Adequate organ and marrow function as defined below:\n\n  1. Leukocytes ≥ 2,000\u002FmcL\n  2. absolute neutrophil count ≥ 1000\u002FmcL\n  3. platelets ≥ 60,000\u002Fmcl\n  4. total bilirubin within normal institutional limits\n  5. AST(SGOT)\u002FALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present\n  6. creatinine \\\u003C1.5ULN\n  7. hemoglobin ≥ 8 g\u002FdL\n  8. Serum albumin ≥ 2.8 g\u002FdL\n  9. Urine protein\u002Fcreatinine ration (UPCR) ≤ 1 mg\u002Fmg\n* The effects of cabozantinib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nBased on its mechanism of action, ipilimumab can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception during treatment with ipilimumab and for 3 months following the last dose of ipilimumab.\n\nBased on its mechanism of action, nivolumab can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception during treatment with nivolumab and for 5 months following the last dose of nivolumab.\n\n1\\. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n1. Has not undergone a hysterectomy or bilateral oophorectomy; or\n2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\n   * Life expectancy of greater than 3 months\n   * Ability to swallow tablets\n   * Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Any type of previous systemic anti-cancer treatment\n* All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline\n* Any locoregional treatment for HCC within 3 months\n* Vp4 or Vp3 portal vein thrombus\n* Extrahepatic disease\n* Patients may not be receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, cabozantinib or other agents used in study.\n* Concomitant anticoagulation with coumarin agents (eg, warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitors (e.g., rivaroxaban), or platelet inhibitors (eg, clopidogrel). Allowed anticoagulants are the following:\n\n  1. Prophylactic use of low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose low molecular weight heparins (LMWH).\n  2. Therapeutic doses of LMWH in subjects with a screening platelet count \\> 100,000\u002FμL, without known brain metastases, and who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n* The subject has prothrombin time (PT)\u002FINR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 28 days before the first dose of study treatment.\n* Uncontrolled intercurrent illness including, but not limited to, the following conditions:\n\n  1. ongoing or active infection\n  2. symptomatic congestive heart failure\n  3. uncontrolled hypertension defined as sustained blood pressure (BP) \\> 150 mm Hg systolic or \\> 100 mm Hg diastolic despite optimal antihypertensive treatment\n  4. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before first dose\n  5. unstable angina pectoris\n  6. cardiac arrhythmia\n  7. evidence of tumor invading GI tract, active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n  8. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.\n\n     Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.\n  9. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose.\n  10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n  11. Lesions invading any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible.\n  12. Other clinically significant disorders that would preclude safe study participation:\n\n      1. Serious non-healing wound\u002Fulcer\u002Fbone fracture\n      2. Uncompensated\u002Fsymptomatic hypothyroidism\n      3. Moderate to severe hepatic impairment (Child-Pugh B or C)\n  13. psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n* Prior treatment with cabozantinib\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment.\n\nCorrected QT (QTc) = QT \u002F ∛RR\n\nQT: duration of QT interval RR: duration of RR interval\n\nNote: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n* History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ and not treated with systemic therapy.\n* Inability to comply with study and follow-up procedures as judged by the Investigator\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants\n* Has fibrolamellar HCC\n* Has received prior cytotoxic, biologic or other systemic anticancer therapy including investigational agents within 4 weeks prior to randomization.\n* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Has received a live vaccine within 30 days prior to the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n* Has severe hypersensitivity (Grade ≥ 3) to nivolumab or cabozantinib and\u002For any of their excipients.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a known history of human immunodeficiency virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n* Has a known history of active tuberculosis (TB; Bacillus tuberculosis).\n* Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":468,"type":23},35,[209],"This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab\u002Fnivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.",[472,473],"Hepatocellular Carcinoma","HCC",[472,473,475,476,477,478,479],"Cabozantinib","Ipilimumab","Nivolumab","TACE","transarterial chemoembolization","2026-06-29",{"date":482,"type":39},"2026-07-01",{"date":484,"type":39},"2020-08-07",{"date":486,"type":23},"2027-09-01",{"name":45,"class":46},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":143,"minAge":19,"maxAge":20,"enrollmentInfo":494,"targetDuration":4,"studyType":24,"phases":495,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":71},"100560600","the-effects-of-core-shamanism-in-fibromyalgia-100560600","NCT06579261","The Effects of Core Shamanism in Fibromyalgia","Inclusion Criteria for Fibromyalgia participants:\n\n* Female\n* Over 18 and under 75 years of age.\n* Fibromyalgia patients and satisfies the 2016 Fibromyalgia Diagnostic Criteria for the classification of FM.\n* Mean recalled pain over the last seven days (7-day recall) greater than or equal to 4 on a 10 cm Visual Analog Scale (VAS) for pain; 7-day recall.\n* Willing to limit the introduction of any new medications or treatment modalities for control of FM symptoms during the study.\n* Able to travel to the study site to receive shamanic treatments up to twice weekly.\n* Understanding and willing to complete all study procedures.\n* Capable of giving written informed consent.\n* Proficient ability to speak, read, and write in english.\n\nExclusion Criteria:\n\n* Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain.\n* History of head injury with substantial loss of consciousness\n* Peripheral neuropathy of known cause that interferes with activities of daily living.\n* Routine daily use of opioid analgesics, marijuana, or history of substance abuse.\n* Stimulant medications, such as those used to treat Attention Deficit Disorder (ADD)\u002FAttention-deficit\u002Fhyperactivity disorder (ADHD). (e.g., amphetamine\u002F dextroamphetamine \\[Adderall®\\], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil), are excluded.\n* Concurrent participation in other therapeutic trials.\n* Use of as needed (PRN) over the counter (OTC) pain medications (Nonsteroidal anti-inflammatory drugs (NSAIDs), etc.) on day of electroencephalogram (EEG) testing.\n* Use of PRN opioid analgesics 48 hours prior to electroencephalogram (EEG) testing.\n* Pregnant or nursing. A pregnancy test will be given prior to electroencephalogram (EEG) sessions.\n* Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years).\n* Contraindications to EEG methods. These may include but are not limited to: surgical clips, surgical staples, metal implants, and certain metallic dental material.\n* Any impairment, activity or situation that is in the judgment of the Study Coordinator or Principal Investigator that would prevent satisfactory completion of the study protocol. This includes unreliable, or inconsistent pain scores as deemed by the principal investigator.\n* Sufficient knowledge of Shamanism techniques that may bias participant outcomes.\n* Presence of factors that may preclude the safe use of the Shamanism intervention.\n* History vascular surgery in lower limbs or current lower limb vascular dysfunction.\n* Presence of uncontrolled cardiovascular disease.\n* Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's fibromyalgia; current involvement in out-of-court settlements for claims pertinent to the subject's fibromyalgia; or currently receiving monetary compensation as a result of any of the above.\n* Inability or unwillingness of an individual to give written informed consent.",{"count":7,"type":23},[26],"This study aims to determine the feasibility of a shamanism intervention for patients with fibromyalgia, acquire efficacy data to determine if Shamanism reduces clinical pain and other common symptoms associated with fibromyalgia, and determine if the Shamanism intervention changes heart rate electrocardiogram (ECG), breathing rate, and brain wave electroencephalogram (EEG) outcomes in fibromyalgia patients and shamanic practitioners.\n\nThe investigators hypothesize that 80% of individuals will complete at least 80% of study visits, clinical pain severity and\u002For interference will be significantly reduced following the Shamanic intervention, and lung, heart, and\u002For brain activity will be altered with the Shamanic intervention and also become more synchronized between Shamanic Practitioners (SPs) and patients during the course of treatment.",[498],"Fibromyalgia",[500],"fibromyalgia chronic pain",{"date":502,"type":39},"2026-06-23",{"date":504,"type":39},"2024-08-01",{"date":69,"type":23},{"name":45,"class":46},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":18,"minAge":144,"maxAge":81,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":71},"100484038","phase-4-treatment-of-menieres-disease-with-migraine-medications-100484038","NCT05582837","Treatment of Meniere's Disease With Migraine Medications","Treatment of Meniere's Disease With Nortriptyline-Topiramate Stepwise Regimen: A Randomized Double-Blinded Clinical Trial","Inclusion Criteria:\n\n1. Patients with active or frequent Meniere's Disease.\n2. Male or female between the ages of 25 to 85 years.\n3. Subject must be compliant with the medication and attend study visits.\n4. Must be able to read and write in the English language to provide consenting.\n\nExclusion Criteria:\n\n1. Pregnancy will result in automatic exclusion from the study. A urine pregnancy test to rule out pregnancy for all women who are of childbearing potential.\n2. Subjects with history of surgery for Meniere's Disease.\n3. Subject with history of an adverse reaction to medication being prescribed.\n4. Subject suffers from a medical condition or has history that may be concerning to the investigator's clinical opinion.\n5. Subjects with psychosis.\n6. Subjects with neurological neoplasm.\n7. All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.",{"count":515,"type":23},40,[260],"Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.",[519],"Ménière",[521],"Meniere's Disease, medication, randomized, trial, migraine","2026-06-17",{"date":524,"type":39},"2026-06-22",{"date":526,"type":39},"2022-08-01",{"date":528,"type":23},"2027-12-30",{"name":45,"class":46},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":173,"enrollmentInfo":536,"targetDuration":4,"studyType":24,"phases":538,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":71},"100559974","analgesic-response-to-opioids-in-patients-with-fibromyalgia-after-conventional-acupuncture-versus-sham-acupuncture-100559974","NCT06571110","Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture","Inclusion Criteria:\n\n* Are 18 - 80 years old\n* have been diagnosed with Fibromyalgia for more than 6 months\n* Are already using chronic, continuous opioid therapy, including but not limited to the use of Hydrocodone (Norco), Oxycodone (Percocet), morphine, methadone or Tylenol #3 daily\n* Have moderate to excruciating pain at baseline, determined by a 5 or greater score on the Visual Analogue Scale (VAS)\n\nExclusion Criteria:\n\n* Are younger than 18 or older than 80 years old\n* Have been diagnosed with a Substance Use Disorder (SUD)\n* Pregnant\n* Have an active litigation or worker's compensation case\n* Have an active mental health diagnosis, such as bipolar disorder, psychosis, or suicidal ideation\n* Are prescribed and actively using low dose Naltrexone . Have tried acupuncture in the last 6 months",{"count":537,"type":23},45,[26],"This study aims to see whether acupuncture can help fibromyalgia patients by giving them acupuncture treatment and seeing whether acupuncture helps enhance the effects of an opioid.",[498],[542],"Acupunture","2026-06-11",{"date":545,"type":39},"2026-06-15",{"date":547,"type":39},"2025-03-15",{"date":549,"type":23},"2027-12-01",{"name":45,"class":46},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":80,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":71},"100325038","acoustic-and-electrical-stimulation-for-the-treatment-of-tinnitus-100325038","NCT03511807","Acoustic and Electrical Stimulation for the Treatment of Tinnitus","Inclusion Criteria:\n\n1. 18 years or older\n2. Male or female\n3. Tinnitus present for 6 months or more\n4. Adequate command of English to reliably describe the unusual sensory percepts provided by electrical stimulation, and to complete surveys.\n5. For patients undergoing electrical stimulation via a cochlear implant, they should have a cochlear implant prior to enrollment (not applicable for acoustic stimulation)\n\nExclusion Criteria:\n\n1. Aged less than 18 years\n2. Active illicit drug use, alcohol dependence\n3. Treatable cause of tinnitus\n4. History of psychosis\n5. Abnormalities of the ear canal or ear drum\n6. Chronic middle ear disease\n7. Subjects on medications known to cause tinnitus (aspirin, ibuprofen, naproxen) which could not be stopped will be excluded.\n8. Pregnant or breastfeeding.",{"count":558,"type":23},100,[26],"Tinnitus, or ringing in the ears, affects 10% to 30% of the population. Of those, 20% have tinnitus bothersome enough to seek medical attention. In many people, tinnitus can significantly affect the quality of life. At this point in time, there is no effective treatment or cure available for tinnitus.\n\nIt has been found that electrical stimulation of the inner ear can reduce and in some cases eliminate tinnitus. The purpose of this research is to investigate both acoustic and electrical stimulation of the inner ear as a possible treatment of tinnitus.\n\nIn both acoustic and electrical testing conditions, the subjects will be instructed to be familiar with a 0-10 ranking scale of loudness. In acoustic testing, the stimulus will be presented through headphones in a noiseless environment, and the subject will be asked to report on the loudness of the presented sound and the level of the tinnitus at 20-second intervals. If the subject cannot perceive the presence of the tinnitus, a value of zero will be assigned. A typical sound will be presented for 3 to 6 minutes. Loudness will be reported for 1 to 4 minutes after stimulus offset to measure the presence and duration of residual inhibition.\n\nElectrical stimulation will be delivered to the inner ear in three ways, 1. using a cochlear implant (implant placed in the inner ear to replace hearing function), 2. Using an electrode placed in the ear canal, and 3. using a small needle inserted through the ear drum. Various electrical signals will be used to evaluate the reduction in the tinnitus perception by the subject. The subjects will rate the loudness of the tinnitus before, during, and after the electrical signal. Surveys will be used to evaluate the tinnitus loudness and the quality of life of the subjects. Hearing tests will be used before and after the procedures. The long term goal of this research is to develop a device to treat tinnitus in people who can hear and to develop programs for cochlear implants that help treat tinnitus in deaf people.",[562],"Tinnitus","2026-06-09",{"date":543,"type":39},{"date":566,"type":39},"2017-01-01",{"date":568,"type":23},"2032-11",{"name":45,"class":46},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":24,"phases":580,"briefSummary":581,"conditions":582,"keywords":583,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":71},"100514214","phase-4-pharmacotherapy-in-conjunction-with-lifestyle-counseling-for-management-of-weight-regain-after-bariatric-surgery-100514214","NCT05975580","Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery","PROJECT-BARI","Inclusion Criteria:\n\n1. Male and female subjects aged 18-70 years\n2. Had sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) at least 18 months ago\n3. Weight regain of ≥5% relative to post-surgery nadir weight\n4. Body mass index (BMI) ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with weight-related comorbidities\n5. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry\n6. Must be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Type 1 diabetes\n2. Insulin-dependent type 2 diabetes\n3. Fasting plasma glucose (FPG) ≥240 mg\u002FdL\n4. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and\u002For diastolic blood pressure (DBP) ≥100 mm Hg on the average of three seated measurements after being at rest for at least 5 minutes\n5. History of significant (as determined by the investigator) and unstable cardiovascular disease including coronary artery disease, arrhythmias, severe congestive heart failure, or stroke\n6. Use of monoamine oxidase inhibitors, current or within 2 weeks\n7. Hyperthyroidism or other significant thyroid disease\n8. Angle-closure glaucoma\n9. Agitated states\n10. History of drug abuse within the past year\n11. Known hypersensitivity or idiosyncrasy to sympathomimetic amines\n12. Severe hepatic disease (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis without portal hypertension or cirrhosis is acceptable)\n13. End-stage renal disease\n14. History of nephrolithiasis\n15. Serum triglycerides ≥500 mg\u002FdL\n16. Cancer, not in remission, within the past 2 years except for adequately treated basal cell, squamous cell skin cancer, or in-situ cervical cancer\n17. History of psychosis or bipolar disorder\n18. Suicidal ideation or unstable\u002Funtreated major depressive disorder within the past year\n19. Use of antidepressant medication that has not been at stable dose for at least 3 months\n20. Hospital Anxiety and Depression Scale (HADS) score of ≥11 for depression or anxiety items\n21. Binge Eating Scale (BES) score of ≥27\n22. Alcohol use disorder within the past year\n23. Epilepsy\n24. Currently taking phentermine or topiramate or the combination, or products containing these drugs\n25. Currently taking stimulants (e.g., Attention Deficit Hyperactivity Disorder medications)\n26. Current use of prescription or over-the-counter weight loss drugs or supplements\n27. Taking prescription or over-the-counter drugs or products, which in the opinion of the PI, could be associated with significant effects on body weight\n28. Planning additional bariatric surgery procedures in the next 13 months\n29. History of revisional bariatric surgery (revisional surgery after adjustable gastric banding is acceptable)\n30. Currently participating in another weight loss program or have plans to participate in the next 13 months\n31. Smoking cessation within the previous 3 months or plans to quit smoking in the next 13 months\n32. Pregnant or breastfeeding or planning pregnancy in the coming 13 months\n33. History of, or any existing condition that, in the opinion of the Principal Investigator, would interfere with the study outcomes or place the subject at unacceptable risk by participating in the study","70 Years",{"count":579,"type":23},120,[260],"This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.",[331],[584,585,586,587],"Bariatric surgery","Weight regain","Antiobesity drugs","Treatment of weight regain","2026-06-05",{"date":563,"type":39},{"date":591,"type":39},"2023-08-29",{"date":593,"type":23},"2028-01-31",{"name":45,"class":46},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":24,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":610,"leadSponsor":612,"locationsCount":71},"100633487","phase-2-fianlimabcemiplimab-as-totalneoadj-the-tnt-formelanoma-100633487","NCT07527325","Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma","Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma","Inclusion Criteria:\n\n* ≥18 years at the time of signing informed consent form (ICF) and able to independently complete informed consent. A certified translator must be used in the completion of informed consent for non-English speaking individuals.\n* Patients must have surgically resectable, macroscopic Stage IIIB-D cutaneous melanoma or oligometastatic resectable stage IV (M1a, M1b, and M1c) melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria. Patients are eligible at the time of the initial diagnosis or recurrence after previous surgery. Patients should have \\> 1 RECIST measurable lesion.\n* Participants must have Eastern Cooperative Group (ECOG) performance status score of 0, 1 or 2 at initial screening.\n* Life expectancy of at least 12 weeks.\n* Adequate bone marrow, liver, and renal function:\n* Hemoglobin \\>8.0 g\u002FdL\n* Platelets \\>75\u002Fmm3\n* ANC \\>1.5\u002Fmm3\n* Creatinine Clearance \\> 30mL\u002Fmin\n* AST and ALT less than 3 times the Upper Limit of Normal. participants with Gilbert's syndrome are excluded if total bilirubin \\> 3.0 × ULN; or direct bilirubin \\> 1.5 × ULN\n* Total Bilirubin \\\u003C 3.1.\n* Albumin ≥ 3.0 g\u002FdL\n* Absolute neutrophil count ≥ 1.5 × 109\u002FL\n* Absolute lymphocyte count ≥ 0.5 × 109\u002FL\n* Women of childbearing potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment.\n* Females of childbearing potential and males must be willing and able to use a highly effective method of contraception to avoid pregnancy for the duration of the study and for at least 6 months after the last dose of study treatment. Acceptable means of contraception are listed in the fianlimab institutional brochure.\n* Male participants must be willing to abstain from donating sperm from the time of enrollment until 6 months after administration of study interventions.\n\nExclusion Criteria:\n\n* Participants with visceral, bone, or brain metastases.\n* Participants with a local recurrence in scar or surgical bed of the primary melanoma as the sole site of disease.\n* Participants with N1a or N2a only disease.\n* Participants with a diagnosis of acral, ocular or mucosal melanoma.\n* Participants with a history of a malignant disease that can interfere with interpretation of study results.\n* Participants with previous treatment with investigational or standard immunotherapy for melanoma or other malignancy.\n* Patients with a history of myocarditis.\n* Patients with a TnT or troponin I (TnI) \\> 2x institutional ULN at baseline. Patients with Troponin T (TnT) or troponin levels between \\> 1 to 2x ULN are permitted if repeat levels within 24 hours are ≤ 1x ULN. If TnT or TnI levels are \\> 1 to 2x ULN within 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment by the investigator based on the medical judgement in the patient's best interest.\n* Participants with known untreated or symptomatic central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Known hypersensitivity to the active substances or to any of the excipients.\n* Participants with a known history of chronic viral infections as indicated below.\n* Known HBV infection defined as hepatitis B surface antigen reactive. NOTE: Participants with HBV infection on stable anti-viral therapy for \\> 4 weeks prior to the planned first study intervention and viral load confirmed as undetectable during Screening may be eligible.\n* Known active HCV infection defined as detectable HCV RNA (qualitative) infection. NOTE: History of HCV is not exclusionary if participant has received curative treatment and viral load is confirmed as undetectable during Screening.\n* HIV infection with CD4 count \\\u003C200\u002Fmicroliter as measured within screening time period. Patients with HIV infectious should be on combination antiretroviral medication.\n* History or current evidence of significant (CTCAE grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication.\n* Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents except for the following: . The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment.\n* Participants with a history of allogeneic tissue\u002Fsolid organ transplant.\n* Live vaccine within 30 days of the planned administration of a study drug.\n* Positive pregnancy test during screening. Pregnant or lactating women are prohibited from enrolling in this study.\n* Participants must not have any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study treatment administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.",{"count":468,"type":23},[209],"This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.",[606],"Melanoma (Skin)","2026-06-03",{"date":588,"type":39},{"date":482,"type":23},{"date":611,"type":23},"2030-02-01",{"name":45,"class":46},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":80,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":620,"targetDuration":4,"studyType":24,"phases":621,"briefSummary":622,"conditions":623,"keywords":626,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":4},"100589308","chatbot-for-online-support-groups-to-treat-tobacco-addiction-100589308","NCT06952725","Chatbot for Online Support Groups to Treat Tobacco Addiction","Intelligent Chatbot for Online Support Groups to Treat Tobacco Addiction","Inclusion Criteria:\n\n* Cigarette smokers (can also use e-cigarettes)\n* Ages 18-75 years\n* English speaking\n* Smart phone with unlimited data\n* 100 cigarettes lifetime\n* Prepared to quit smoking within 10 days of study start\n* Active text and email\n* Use of social media or group messaging\n* Home address provided\n* Contact information for a collateral provided\n* Setup of a GroupMe account for study\n\nExclusion Criteria:\n\n* No NRT health contraindications\n* 5+ cigarettes per day\n* Not an illicit drug user\n* Not a daily marijuana\u002Fcannabis user",{"count":579,"type":23},[26],"Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). In the intervention arm (N=60), each support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). The intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot. But both the intelligent chatbot and the automated message-posting bot will post a pre-written daily discussion topic to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding.",[624,625],"Tobacco Dependence","Tobacco Use Disorder",[627,628,629],"tobacco use addiction","online support group","chatbot","2026-05-20",{"date":632,"type":39},"2026-05-22",{"date":634,"type":23},"2026-12-01",{"date":636,"type":23},"2028-06-01",{"name":45,"class":46},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":646,"maxAge":577,"enrollmentInfo":647,"targetDuration":4,"studyType":648,"phases":4,"briefSummary":649,"conditions":650,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":71},"100610360","mapping-ibogaine-neural-dynamics-in-opioid-use-disorder-100610360","NCT07226570","Mapping Ibogaine Neural Dynamics in Opioid Use Disorder","Central Neural Actions of Ibogaine in Opioid Use Disorder (OUD)","MIND-OUD","Inclusion Criteria:\n\n* Adults aged 21-70 with confirmed moderate to severe OUD as assessed by equal or greater than 4 symptoms using DSM-5 criteria.\n* Independently scheduled to receive ibogaine treatment at Ambio Life Sciences in Tijuana, Mexico.\n* Able to undergo MRI and EEG procedures at UC Irvine at Visit 1 (baseline), Visit 4, and Visit 5, totaling three sessions.\n* Able to complete psychometric surveys at each study time point.\n* Able to provide urine samples at all three scanning sessions at UCI.\n* Able to provide urine samples at a local external lab for 3- and 6-month follow-ups.\n* Capable of giving written informed consent.\n* Proficient ability to speak, read, and write in English.\n\nExclusion Criteria:\n\n* Presence of known past procedures, devices in the body, claustrophobia, or other contraindications for MRI.\n* Use of any psychedelic substances within 3 months prior to screening.\n* Diagnosis of schizophrenia, bipolar disorder (type I or II), or borderline personality disorder.\n* Use of ibogaine within 6 months prior to screening.\n* Pregnant or nursing. Participants who become pregnant during the study will be withdrawn from further participation.\n* Diagnosis of epilepsy or history of seizures.\n* Other contraindications to MRI\u002FEEG methods. These may include but are not limited to: brain surgical clips and surgical staples, metal implants in the brain, and certain metallic dental material.\n* Inability to complete MRI\u002FEEG sessions or follow-up visits.\n* Inability or unwillingness of an individual to give written informed consent.\n\nNote: UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant.","21 Years",{"count":55,"type":23},"OBSERVATIONAL","This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in this study will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S. The University of California, Irvine (UCI) research team will not provide the treatment but will conduct brain imaging, administer psychometric questionnaires, and obtain urine samples throughout the course of this study. UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant.\n\nThe main goal is to see if ibogaine changes brain function as assessed with magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG). MRI\u002FMRS will measure brain activity when participants view opioid-related images, brain connectivity at rest, and levels of brain chemicals involved in craving and substance use. EEG will measure brain wave activity. MRI\u002FMRS\u002FEEG will be administered across 3 study time points. In addition, participants will complete psychometric surveys related to opioid craving, withdrawal symptoms, mood, anxiety, pain, and quality of life, along with urine tests to monitor substance use and screen for pregnancy.\n\nThe investigators hypothesize that after ibogaine treatment, participants will show reduced brain responses to opioid cues, changes in brain connectivity and chemistry, and improvements in self-reported cravings and other symptoms. This information may help researchers better understand how ibogaine works in the brain and whether it could play a role in future treatments for OUD.",[651],"Opioid Use Disorder (OUD)","2026-05-15",{"date":654,"type":39},"2026-05-18",{"date":656,"type":39},"2025-09-08",{"date":658,"type":23},"2027-05",{"name":45,"class":46},""]